# Supplementary Appendix

Supplement to: Epstein JN, Garner AA, Kiefer AW, et al. Trial of training to reduce driver inattention in teens with ADHD. N Engl J Med 2022;387:2056-66. DOI: 10.1056/NEJMoa2204783

This appendix has been provided by the authors to give readers additional information about the work.

## Table of Contents for Supplementary Appendix

С	Contents	Pages
1.	Table S1: Representativeness of study participants	3-5
2.	Table S2: Sample rates of psychiatric comorbidity	6
3.	Randomization method	6
4.	Figure S1: Driving simulation figure	7
5.	Power analysis	7-8
6.	Missing data handling	8-10
7.	Figure S2: Missing data modeling for standard deviation of lane position	9
8.	Table S3: Adverse events table	11
9.	Figure S2: Graph of FOCAL+ vs. control training effects on long	
	glances	12
10.	Figure S3: Graphs of FOCAL+ vs. control training effects on standard devia	tion
	of lane position	13
11.	Moderation analysis – stimulant medication	13-15
12.	Table S4: FOCAL+ and Control Training Effects Across Teens Taking and N	lot
	Taking Stimulant Medication	14
13.	COVID-19 sensitivity analysis	15-16
14.	Table S5: Driving simulation outcomes across Control and FOCAL+ training	
	groups at 1-month and 6-months post-training – Limited to teens whose 1-ye	ear
	of naturalistic driving ended prior to COVID-19 Restrictions	15

#### Trial of Training to Reduce Driver Inattention in Teens with ADHD

Jeffery N. Epstein, Ph.D.,<sup>1,2</sup> Annie Artiga Garner, Ph.D.,<sup>3</sup> Adam W. Kiefer, Ph.D.,<sup>4</sup>

James Peugh, Ph.D.,<sup>1,2</sup> Leanne Tamm, Ph.D.,<sup>1,2</sup> Ryan P. MacPherson, M.S.,<sup>4</sup>

John O. Simon, M.A.,<sup>1</sup> & Donald L. Fisher, Ph.D.<sup>5,6</sup>

#### <sup>1</sup>Department of Pediatrics, Cincinnati Children's Hospital Medical Center

<sup>2</sup>University of Cincinnati College of Medicine

<sup>3</sup>Department of Psychology, Saint Louis University

<sup>4</sup>Department of Exercise and Sport Science, University of North Carolina at Chapel Hill

<sup>5</sup>Department of Mechanical and Industrial Engineering, University of Massachusetts Amherst

<sup>6</sup>Volpe National Transportation Systems Center, U.S. Department of Transportation

# 1. Representativeness of Study Participants

Table S1. Representativeness of Study Participants			
Category	Example		
Disease, problem, or condition	Attention-Deficit/Hyperactivity Disorder (ADHD)		
under investigation			
Special considerations related to:			
Age	As children age, hyperactivity/impulsivity		
	symptoms of ADHD become less prominent,		
	while symptoms of inattention persist (APA,		
	2013).		
Sex and gender	ADHD affects males more than females,		
	typically at a 2:1 ratio (APA, 2013), with females		
	more likely than males to present primarily with		
	inattentive features.		
Race/Ethnicity	Incidence rates for ADHD are highest in White		
	children, slightly lower in Black and Hispanic		
	children, and lowest for Asian children (Shi et al,		
	2021). Black and Hispanic drivers are less likely		
	than non-Hispanic White drivers to get their		
	driver's license before age 18 (Shults, Banerjee,		
	& Perry, 2016; Lefft, Williams, & Grabowski,		
	2014; Vaca et al., 2021).		
Other considerations	ADHD is typically treated with stimulant		
	medication, particularly in adolescents and		
	young adults, for whom there are fewer		
	benavioral/psychosocial treatments (Pelham &		
	Fabiano, 2008; Smith, Waschbusch,		
	Willoughby, & Evans, 2000).		

Trialdemonstrated the expect females. There was a hi White participants than o in the study, and the per Hispanic participants way expected given national rates. Data from the 202 that the ethnic composit Cincinnati metropolitan : 12% African American; and 3% biracial/multirac 2019). However, White of to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, ; (Halbrook et al., 2016), sample (M = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parti- stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or clatino/a. Each of the hyperactive/impulsives y a 4-point scale (0enevel 2-often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medical learning emotional or based to specify ra reported as Hispanic or or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (Wol Stimulant medication us series of questions rated Do you take any medical learning emotional or brain learning emotional or brain learn	current trial
females. There was a hi White participants than i in the study, and the per Hispanic participants wa expected given national rates. Data from the 202 that the ethnic composit Cincinnati metropolitan a 12% African American, i and 3% biracial/multirac 2019). However, White 0 to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), g sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parti- stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never) 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions ratec Do you take any medica learning, emotional or b	cted ratio of males to
White participants than in the study, and the per Hispanic participants we expected given national rates. Data from the 202 that the ethnic composit Cincinnati metropolitan a 12% African American, i and 3% biracial/multirac 2019). However, White of to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parti- stimulant medication to Information on age, sex, obtained on a questionm participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medical learning, emotional or bor you take any medical participants or you take any m	igher percentage of
in the study, and the per- Hispanic participants wa expected given national rates. Data from the 202 that the ethnic composit Cincinnati metropolitan a 12% African American, i and 3% biracial/multirac 2019). However, White 4 to receive their driver's I (Shults, Tanerjee, & Per- Williams, & Grabowski, i (Halbrook et al., 2016), g sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parti- stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevel 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or balls	other racial categories
Hispanic participants wa expected given national rates. Data from the 202 that the ethnic composit Cincinnati metropolitan a 12% African American, a and 3% biracial/multirac 2019). However, White to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), g sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parti- stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African A Merican Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevel 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medical learning, emotional or ba learning, emotional or ba learn	rcentage of Black and
expected given national rates. Data from the 202 that the ethnic composit Cincinnati metropolitar 12% African American, i and 3% biracial/multirac 2019). However, White i to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, i (Halbrook et al., 2016), s sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partis stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	as somewhat lower than
rates. Data from the 202 that the ethnic composit Cincinnati metropolitan 12% African American, 3 and 3% biracial/multirac 2019). However, White to receive their driver's 1 (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), s sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partis stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevel 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	and local prevalence
that the ethnic composit Cincinnati metropolitan 12% African American, and 3% biracial/multirac 2019). However, White 4 to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), 9 sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parti- stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	20 US Census indicates
Cincinnati metropolitan 12% African American, i and 3% biracial/multirac 2019). However, White of to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, . (Halbrook et al., 2016), g sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of parting stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacifi other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medical learning, emotional or heir	tion of the greater
12% African American, 3 and 3% biracial/multirac 2019). However, White of to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, . (Halbrook et al., 2016), 9 sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African <i>A</i> American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or heir	area is 79% Caucasian,
and 3% biracial/multirac 2019). However, White of to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), y sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African <i>A</i> American Indian or Alas Hawaiian or Other Pacifi other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medical learning, emotional or here	3% Hispanic, 3% Asian,
2019). However, White 4 to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), 9 sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevel 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or br	cial (US Census Bureau,
to receive their driver's I (Shults, Tanerjee, & Per Williams, & Grabowski, : (Halbrook et al., 2016), y sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African <i>A</i> American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or br	drivers are more likely
(Shults, Tanerjee, & Per Williams, & Grabowski, (Halbrook et al., 2016), s sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African <i>A</i> American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevet 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	license prior to age 18
Williams, & Grabowski, J (Halbrook et al., 2016), y sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African <i>A</i> American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevel 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	rry, 2016; Tefft,
(Halbrook et al., 2016), y sample ( $M = 17.38$ year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African // American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	2014). As expected
sample ( <i>M</i> = 17.38 year symptom ratings were h hyperactivity/impulsivity baseline, 68.4% of partie stimulant medication to Information on age, sex, obtained on a questionm participants or their care current age were provid male (0) or female (1). F White, Black or African // American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	given the age of our
symptom ratings were in hyperactivity/impulsivity baseline, 68.4% of parties stimulant medication to Information on age, sex, obtained on a questionin participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	S, SD = .93), mailentive
baseline, 68.4% of parties stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provide male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=nevel 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	Ngher than
stimulant medication to Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	symptom ratings. At
Information on age, sex, obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	manage their ADHD
obtained on a questionn participants or their care current age were provid male (0) or female (1). F White, Black or African // American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	and race/ethnicity was
participants or their care current age were provid male (0) or female (1). F White, Black or African American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	aire completed by
current age were provid male (0) or female (1). F White, Black or African American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	egivers. Date of birth and
male (0) or female (1). F White, Black or African American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	led; sex was coded as
White, Black or African / American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	Race was reported as
American Indian or Alas Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medical learning, emotional or be	American, Asian,
Hawaiian or Other Pacif other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	skan Native, Native
other was selected, the were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	fic Islander, or Other (if
were asked to specify ra reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	participant or caregiver
reported as Hispanic or or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	ace). Ethnicity was
or Latino/a. Each of the hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	Latino/a or Not Hispanic
hyperactive/impulsive sy a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or be	ADHD inattentive and
a 4-point scale (0=never 2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or be	ymptoms were rated on
2=often, 3=very often) o Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica	r, 1=occasionally,
Assessment Scale (Wol Stimulant medication us series of questions rated Do you take any medica learning, emotional or be	on the Vanderbilt Parent
Sumulant medication us series of questions rated Do you take any medica learning, emotional or be	Iraich et al., 2003).
Do you take any medica	d by the participant (i.e.
learning emotional or be	a by the participant (i.e.,
	anona for anerritori, analyzioral difficultios?
Vae/No: What is the nar	me of the medication?
l ist of 39 medications n	provided to select from
and an "Other" category	/.)
Yes/No; What is the nar List of 39 medications p	me of the medication? provided to select from

- American Psychological Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders* (5th ed.). Author.
- Holbrook, J. R., Cuffe, S. P., Cai, B., Visser, S. N., Forthofer, M. S., Bottai, M., Ortaglia, A., & McKeown, R. E. (2016). Persistence of Parent-Reported ADHD Symptoms From Childhood Through Adolescence in a Community Sample. *Journal of Attention Disorders*, 20(1), 11–20. https://doi.org/10.1177/1087054714539997
- Pelham W.E., Fabiano G.A. Evidence-based psychosocial treatments for attentiondeficit/hyperactivity disorder. *Journal of Clinical Child and Adolescent Psychology*, 37 (2008), pp. 184-214
- Shults, R.A., Banerjee, T. & Perry, T. (2016) Who's not driving among U.S. high school seniors: A closer look at race/ethnicity, socioeconomic factors, and driving status, *Traffic Injury Prevention*, 17:8, 803-809, DOI: <u>10.1080/15389588.2016.1161761</u>
- Smith B., Waschbusch D., Willoughby M., Evans S. The efficacy, safety and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). *Clinical Child and Family Psychology Review*, 3 (2000), pp. 243-267
- Shi, Y., Hunter Guevara, L. R., Dykhoff, H. J., Sangaralingham, L. R., Phelan, S., Zaccariello, M. J., & Warner, D. O. (2021). Racial Disparities in Diagnosis of Attention-Deficit/Hyperactivity Disorder in a US National Birth Cohort. *JAMA Network Open, 4*(3), e210321-e210321. https://doi.org/10.1001/jamanetworkopen.2021.0321
- Tefft, B.C., Williams, A.F. & Grabowski, J.G. Driver licensing and reasons for delaying licensure among young adults ages 18-20, United States, 2012. *Injury Epidemiology.* 1, 4 (2014). <u>https://doi.org/10.1186/2197-1714-1-4</u>
- U.S. Census Bureau. American Community Survey 1-year estimates. 2019; http://censusreporter.org/profiles/31000US17140-cincinnati-oh-ky-in-metro-area/.
- Vaca, F. E., Li, K., Tewahade, S., Fell, J. C., Haynie, D. L., Simons-Morton, B. G., & Romano, E. (2021). Factors Contributing to Delay in Driving Licensure Among U.S. High School Students and Young Adults. *Journal of Adolescent Health, 68*(1), 191-198. https://doi.org/10.1016/j.jadohealth.2020.05.003
- Wolraich, M. L., Lambert, W., Doffing, M. A., Bickman, L., Simmons, T., & Worley, K. (2003). Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. *Journal of Pediatric Psychology*, 28, 559-567. https://doi.org/10.1093/jpepsy/jsg046

#### 2. Sample sociodemographics and rates of psychiatric comorbidity

Table S2: Sociodemographics and rates of psychiatric diagnoses across all participants and					
within the FOCAL+ and Control groups					
	All	FOCAL+	Control		
	participants	( <i>n</i> =76)	( <i>n</i> =76)		
	( <i>n</i> =152)				
Sociodemographics					
Maternal/paternal education (highest)					
High school graduate [N (%)]	18 (11.9)	5 (6.6)	13 (17.1)		
Bachelor's degree [N (%)]	64 (42.1)	38 (50.0)	26 (34.2)		
Graduate degree [N (%)]	66 (43.4)	32 (42.1)	34 (44.7)		
Unknown [N (%)]	4 (2.6)	1 (1.3)	3 (3.9)		
Family income (dollars)					
0 - \$40,000 [N (%)]	8 (5.3)	3 (3.9)	5 (6.6)		
\$40,001 - \$80,000 [N (%)]	28 (18.4)	15 (19.7)	13 (17.1)		
\$80,000+ [N (%)]	116 (76.3)	58 (76.3)	58 (76.3)		
Unknown	1 (0.7)	1 (1.3)	0 (0.0)		
Psychiatric Comorbidities*					
Oppositional Defiant Disorder [N (%)]	11 (7.2)	5 (6.6)	6 (7.9)		
Anxiety Disorder (includes GAD and PTSD) [N (%)]	32 (21.1)	11 (14.5)	21 (27.6)		
Mood Disorder (includes Depression, Dysthymia, &	15 (9.9)	4 (5.3)	11 (14.5)		
Mania) [N (%)]					
Notes: FOCAL+: Enhanced FOcused Concentration and Attention Learning; KSADS: Schedule					
for Affective Disorders and Schizophrenia for School-Aged Children; GAD: Generalized Anxiety					
Disorder; PTSD: Post-Traumatic Stress Disorder; *based on KSADS interview					

#### 3. Randomization method

Participants were randomized to the two training groups according to a 1:1 ratio. The randomization scheme was done using blocks of 10 so that for every 10 participants, 5 were randomized to each group. A data manager (JS) generated the allocation sequence using the Microsoft Excel random number function. At study outset, each assignment for the full sample was placed in sequentially numbered sealed envelopes. When participants attended the initial training visit, the randomization envelope for that participant was opened at which time the participant's randomized group was revealed to the individual conducting the participant's training.

#### 4. Driving Simulation Figure



**Figure S1**: Driving evaluation consisted of two simulated 15-minute drives. Approximately once per minute, the driver was alerted with an auditory and visual cue (i.e., a letter on the dashboard). Within 20 secs, they were asked to identify how many roads started with the target letter on a GPS map displayed on the simulated center console (map search task).

#### 5. Power Analyses

Effect size estimates from our preliminary data suggested a single FOCAL+ training session improves extended eye glances among teens with ADHD with an effect size (Cohen's *d*) of 1.19. Since this effect size will surely diminish over the course of the 1-year of assessments, we used a conservative effect size estimate of .6 to power our research hypotheses. Monte Carlo simulation power analyses were performed under the following assumptions: (a)  $\alpha$ <.05 (two-tailed); (b) FOCAL+ effect size of .6, (c) effect size of .10 for our sham training, and (d) inclusion of months of driving experience as a covariate. Power analysis with these assumptions indicated that sample sizes of N = 43 per group with complete data at 1-month and 6-month time points will result in power  $\geq$  .80 to detect an adjusted mean difference  $(\bar{X}_{Adj.}) \leq$  -0.36 in standard deviation of lane position between FOCAL+ and control groups and an incidence rate ratio  $\leq$  0.88 between FOCAL+ and control groups for count of long glances.

However, the original grant application (see Aim #4 in original protocol) included additional aims to examine potential moderators of training effects. These moderators included

baseline cognitive performance, ADHD symptom severity, and psychiatric comorbidities. Power analyses for detecting moderation effects suggested that we would require a sample size of 136 with complete data at 1-month and 6-month timepoints to provide 80% power.

Note that we powered based on complete data at 1-month and 6-month timepoints because we were unsure about rates of sample retention given the nature of the patient population (i.e., teens with ADHD). Hence, when we reached our original goal of randomizing 136 participants, we examined rates of retention at that point and estimated how many additional participants would be required to achieve 136 participants with completed data at the 1- and 6- month timepoints. The calculation suggested that we needed to recruit a randomized sample size of 152 to achieve 136 participants with 1- and 6-month simulator outcomes (primary endpoints). Note that this strategy largely worked as we had 135 participants with complete data at the 1-month timepoint and 135 participants with complete data at the 6-month timepoint.

To avoid listwise deletion and to be able to conduct an intent-to-treat analyses, we used imputation for any missing data (see section 6). For our intent-to-treat analyses for our primary outcomes with the full complement of randomized participants, N=152 (n=76 per group) participants provided 96% power to detect an incidence rate ratio of  $\leq$  0.88 between FOCAL+ and controls for count of long-glances and an adjusted mean difference of  $\leq$  -0.36 for standard-deviation of lateral-position between FOCAL+ and controls.

#### 6. Missing Data Handling

#### Primary Analyses (see manuscript)

Two different types of multiple imputation models, data analysis model-based imputation, and fully-conditional specification imputation (Enders, 2010; Graham, 2012; Muthén & Muthén, 1998-2017, p. 576), were used to handle primary analysis missing data because the two primary outcomes were measured on two different scales. Missing data for standard-deviation of lane-position, a continuous response variable, was handled using model based imputation assuming a normal distribution. Specifically, a model in which specific driving simulator "runs" (level 1) nested within drive types over time (level 2) across participants (level 3) formed the foundation of the missing data imputation model. A binary indicator of the specific driving simulator "run" was the sole level 1 predictor of standard-deviation of lane-position ("DV"), and that effect was allowed to vary across driving types at level 2 (i.e., slope variance: "RUN1VAR"). Binary indicators of 1-month ("DriveType 1") and 6-month ("DriveType 2") predicted both standard-deviation of lane-position ("DV") and the variation in the effect of specific "run" as a predictor of standard-deviation of lane-position ("RUN1VAR") at level 2. and all four of those predictive effects (shown as "Dr1 DV", "Dr2 DV", "Dr1 Run1", "Dr2 Run1") were allowed to vary across participants at level 3. Randomization ("TxGroup") was entered as a level 3 predictor of all 5 sources of variance ("Run1Var", "Dr1 DV", "Dr2 DV", "Dr1 Run1", "Dr2 Run1"). Driving experience, a level 3 covariate, was included in the model as a predictor of standard-deviation of lane-position ("DV") variance across participants. The standard-deviation of lane-position multiple imputation model is represented graphically in the figure below.



Figure S2: Missing data modeling for standard deviation of lane position.

Missing data for long-glances, a Poisson-distributed count response variable, could not be imputed with the same 3-level model used to impute missing standard-deviation of lane-position data. Currently, there is no statistical analysis software package capable of imputing missing 3-level count response variable data. In fact, only Mplus (version 8.8) is capable imputing missing multilevel count data, but only under two conditions: 1.) the imputation model can have no more than two levels, and 2.) missing count of long-glances data can only be imputed with a fully conditional specification (or  $H_A$ :) model. As such, the multiple imputation model used to handle missing long - glance data is different from the imputation model used to handle missing standard-deviation of lane-position data in two ways: 1.) a 2-level imputation model, where long-glances variation in driving "runs" nested within post-baseline "drive types" constituted the level 1 model, and long-glances variation in driving information (i.e., means, variances [where applicable], and covariances [where applicable]) at both levels was used to impute missing long-glances data.

M = 100 imputed datasets were generated for all multiple imputation models. Imputed standard-deviation of lane-position and long-glances primary outcomes data were analyzed using generalized estimating equations (GEE) allowing response variable data non-independence from "runs" nested within "drive types" across participants to be modeled. Specifically, the standard-deviation of lane-position GEE model was specified using a normal distribution assumption with an identity link function. The GEE for long-glances, a count variable, was modeled specifying a Poisson distribution and a natural logarithmic link function. All primary and secondary GEE analyses of imputed data pooled the estimates based on Rubin's rules, and all standard errors were computed based on the average standard errors across imputations and the parameter estimate variation across imputations (Rubin, 1987; Schafer, 1997).

#### Secondary Analyses (see manuscript)

The two outcomes for the secondary analyses, off-road glances and crash/near crash were both measured on a binary scale. Some participants did not have any events either due to the DriveCam not being installed in their car or they did not have any events. Such missing data was not imputed, and we conducted non intent-to-treat analysis using those participants with event data. There was no missing data for the 'crash/near crash' secondary outcome across events for those with a DriveCam installed. The GEE analysis for the 'crash/near crash' outcome was performed using all participants with DriveCam event data available. However, long glance data was missing for some events due to unforeseen circumstances (e.g., DriveCam view obstruction or participant driver was wearing sunglasses). Missing data for the 'long-glance' outcome was imputed using GEE model-based imputation. Specifically, a logistic link function was used within a missing data imputation model that allowed the effect of random assignment to predict the presence (=1) or absence (=0) of long-glances nested within participants while controlling for months of driving experience and days DriveCam was operational in vehicle.

Enders, C. K. (2010). Applied missing data analysis. New York: Guilford Press.

Graham, J. W. (2012). *Missing data: Analysis and design*. Springer Science & Business Media.

- Muthén, L.K. and Muthén, B.O. (1998-2017). Mplus User's Guide. (8th ed.). Los Angeles, CA: Muthén & Muthén
- Rubin, D. B. (1988, August). An overview of multiple imputation. In *Proceedings of the survey* research methods section of the American statistical association (pp. 79-84). Princeton, NJ, USA: Citeseer.

Schafer, J. L. (1997). Analysis of incomplete multivariate data. CRC press.

# 8. <u>Adverse Events Table</u>

Table S3. Adverse events across all participants and within the FOCAL+ and Control groups				
	All Participants (n=152)	FOCAL+ ( <i>n</i> =76)	Control ( <i>n</i> =76)	p- value*
	# (%) of	# (%) of	# (%) of	
	Subjects	Subjects	Subjects	
Simulator Sickness including nausea and headache during assessment±	2 (1%)	0 (0%)	2 (3%)	0.50
Simulator Sickness including nausea and headache during training±	10 (7%)	6 (8%)	4 (5%)	0.75
Frustration with simulator training	2 (1%)	2 (3%)	0 (0%)	0.50
*p-value from Fisher's Exact Test comparing $\overline{FOCAL}$ to Control; $\pm$ Of these participants who reported simulator sickness during a training or assessment, all but two (one in each group) went on to complete their 1-month and 6-month drives. FOCAL+: Enhanced FOcused Concentration and Attention Learning				

### 9. <u>Graph of FOCAL+ vs. Control Training Effects on Number of Long Eye Glances Away from</u> <u>Roadway</u>



**Figure S3**: Mean number (with 95% confidence intervals) of long-glances per 15 minute run (adjusted for months of driving experience) during driving simulation among teens with ADHD across FOCAL+ and Control groups after controlling for driver's experience. FOCAL+: Enhanced FOcused Concentration and Attention Learning



10. Graph of FOCAL+ vs. Control Training Effects on Standard Deviation of Lane Position

**Figure S4**: Mean (with 95% confidence intervals) standard-deviation of lane-position (adjusted for months of driving experience) during driving simulation among teens with across FOCAL+ and Control groups after controlling for driver's experience. FOCAL+: Enhanced FOcused Concentration and Attention Learning

#### 11. Moderation Analyses - Medication

While an overall beneficial effect of FOCAL+ compared to Control is reported in the primary analyses, it is possible that FOCAL+ effectiveness was moderated by ADHD medication given the known impact of stimulant medication on improving driving in teens with ADHD (Chang et al., 2017). Of the 140 teens who completed a medication use questionnaire during the 1-year of naturalistic driving, 46 (68.7%) teens in the FOCAL+ group took stimulant medication and 53 (72.6%) teens in the Control group took stimulant medication. It is possible that FOCAL+ training was moderated by teen's medication status.

For the driving simulation outcomes, we examined whether the improvements from baseline to 1-month post-training and baseline to 6-months post-training were moderated by medication status. These analyses were not intent-to-treat since only the 140 teens for whom we had information about medication status during the 1 year of follow-up were included in these analyses. Adjusted mean differences for standard-deviation of lane-position and incident rate ratios for count of long glances were computed using multiple group analysis methods. Specifically, conditional on months of driving experience, training group difference statistics were computed separately across binary medication status.

For DriveCam outcomes, relative risk statistics for binary indicators of long glances and crash/near crash were computed conditional on both months of driving experience and days of DriveCam installation. Specifically, relative risk statistics were computed separately across binary medication status.

Table S4 reports on the results of these analyses.

**Table S4**. FOCAL+ and Control Training Effects Across Teens Taking and Not Taking Stimulant

 Medication

Medication Status	Driving Simulation Outcomes*	FOCAL+ (N=76)	Control (N=76)	Incidence Rate Ratio [95% Cl])*
Medicated	Count of long-glances/15 min	16.57	27.03	0.61
	<ul> <li>– 1-month post-training</li> </ul>	(13.81, 19.33)	(24.72, 29.34)	(0.46, 0.76)
Non-	Count of long-glances/15 min	19.45	27.86	0.70
medicated	<ul> <li>– 1-month post-training</li> </ul>	(15.77, 23.13)	(24.24, 31.48)	(0.49, 0.91)
Medicated	Count of long-glances/15 min	15.63	26.66	0.58
	– 6-months post-training	(12.98, 18.28)	(24.42, 28.90)	(0.44, 0.72)
Non-	Count of long-glances/15 min	20.00	25.86	0.78
medicated	– 6-months post-training	(16.91, 23.08)	(21.69, 30.04)	(0.55, 1.01)
				Adjusted
				Niedn Difforonco*
Medicated	Standard-deviation of lane-	0.90	1 20	-0.30
modibatod	position $-1$ -month post-	(0.85, 0.96)	(1.09, 1.31)	(-0.42, -0.17)
	training		(	( ••••=, •••••)
Non-	Standard-deviation of lane-	0.96	1.06	-0.11
medicated	position – 1-months post-	(0.85, 1.07)	(0.97, 1.16)	(-0.26, 0.04)
	training			
Medicated	Standard-deviation of lane-	0.92	1.25	-0.32
	position – 6-month post-	(0.87, 0.98)	(1.13, 1.36)	(-0.45, -0.20)
	training			
Non-	Standard-deviation of lane-	0.96	1.02	-0.06
medicated	position – 6-months post- training	(0.79, 1.12)	(0.92, 1.12)	(-0.26, 0.13)
	DriveCam outcomes**	FOCAL+ (N=72) no./total events	Control (N=72) no./total events	Adjusted Relative Risk**
Medicated	Long-glance	( /0)	(70)	
Medicaled	Long-glance	(19%)	(29%)	(0.56, 0.87)
Non-	Long-glance	208/894	165/411	0.62
medicated		(23%)	(40%)	(0.43, 0.81)
Medicated	Crash/Near crash	60/1621	123/1919	0.59
		(4%)	(6%)	(0.35, 0.99)
Non-	Crash/Near crash	39/1139	33/656	0.69
medicated		(3%)	(5%)	(0.33, 1.45)
FOCAL+: Enhanced FOcused Concentration and Attention Learning; *Mean values and difference values are adjusted for teen's driving experience. Numbers in parentheses are ± 95% confidence interval. **Relative risks are adjusted for teen's driving experience (months) and number of days DriveCam operational in car. The widths of confidence intervals are not adjusted for multiple				

comparisons and no definite conclusions can be drawn from these results.

Chang Z, Quinn PD, Hur K, et al. Association between medication use for attentiondeficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017;74:597-603.

#### 13. COVID-19 Sensitivity Analysis

Recruitment for this study was performed between December 21, 2016 and March 4, 2020. The final participant's conclusion of their 1-year of naturalistic driving occurred on November 25, 2021. COVID-19 related restrictions began on March 15, 2020. With the institution of COVID-19 restrictions, teen driving patterns may have been affected due to remote schooling, closed businesses, etc. (Stavrinos et al., 2020). Hence, it is important to assess whether the observed benefits of FOCAL+ were impacted by COVID-19 related driving patterns.

For 56 (FOCAL+: n=29 teens; Control: n=27 teens) of the 152 participants, their 1-year of naturalistic driving included days beyond March 15, 2020 when COVID restrictions were put into place. We conducted a sensitivity analyses of our naturalistic driving results by re-running our primary and secondary analyses but including only the 96 teens (FOCAL+ n=47; Control n=49) whose 1-year of naturalistic driving ended prior to COVID restrictions. Below are results of those analyses. Note that the widths of confidence intervals are not adjusted for multiple comparisons and no definite conclusions can be drawn from these results.

	Control		Incidence Pote Potio
	Control	FUCAL+	Incidence Rate Ratio
	(N=49)	(N=47)	(95% CI)
Primary outcomes*			
Count of long-glances/15 min – 1-	29.89	17.82	0.63
month post-training	(27.31, 32.47)	(14.83, 20.78)	(0.49, 0.76)
Count of long-glances/15 min – 6-	29.40	17.10	0.61
months post-training	(26.95, 31.84)	(14.20, 20.01)	(0.48, 0.74)
			Adjusted Mean
			Difference*
			(95% CI)
Standard-deviation of lane-position -	1.18	0.97	-0.22
1-month post-training	(1.11, 1.26)	(0.89, 1.05)	(-0.30, -0.13)
Standard-deviation of lane-position –	1.20	1.01	-0.19
6-months post-training	(1.11, 1.29)	(0.93, 1.08)	(-0.29, -0.10)

**Table S5.** Driving Simulation Outcomes Across Control and FOCAL+ TrainingGroups at 1-Month and 6-Months Post-Training – Limited to Teens whose 1-year of NaturalisticDriving Ended Prior to COVID-19 restrictions

FOCAL+: Enhanced FOcused Concentration and Attention Learning; \*All mean values and difference values are adjusted for teen's driving experience. Numbers in parentheses are ± 95% confidence interval. The widths of confidence intervals are not adjusted for multiple comparisons and no definite conclusions can be drawn from these results.

With the sample constrained to include only teens whose 1 year of naturalistic post-training driving did not encompass COVID-19 restrictions, FOCAL+ teens had a relative risk of 0.73 (95% confidence interval [CI], 0.55 to 0.91) of having a long-glances and a relative risk of 0.60 (95% CI, 0.38 to 0.96) of having a crash/near crash event compared to control teens.

Stavrinos, D., McManus, B., Mrug, S., He, H., Gresham, B., Albright, M. G., ... & White, D. M. (2020). Adolescent driving behavior before and during restrictions related to COVID-19. *Accident Analysis & Prevention*, *144*, 105686.